Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Single and Multiple Dose Study of MK-2828 in Healthy Japanese Participants
jRCT2031250736Phase 1Completed
- Sponsor
- Merck & Co.
- Start
- Mar 2026
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 1 trial of MK-2828 in heart failure with preserved ejection fraction (HFpEF) (4 arms), sponsored by Merck & Co. Primary endpoints: Adverse events and Discontinuation due to adverse events. Started Mar 2026; status: completed.
02
Drugs
MK-2828
03
Conditions
heart failure with preserved ejection fraction (HFpEF)
Beyond the preview
Go deeper on jRCT2031250736.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2031250736.